Oruka Therapeutics, Inc.
ORKA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $27 | $111 | $114 | $91 |
| Gross Profit | -$27 | -$111 | -$114 | -$91 |
| % Margin | – | – | – | – |
| R&D Expenses | $75,060 | $1,013 | $4,464 | $13,832 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13,036 | $6,172 | $5,263 | $5,412 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $88,096 | $7,185 | $9,727 | $19,244 |
| Operating Income | -$88,123 | -$7,296 | -$9,841 | -$19,335 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,399 | $1,957 | -$85 | $13 |
| Pre-Tax Income | -$83,724 | -$5,339 | -$9,926 | -$19,322 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$83,724 | -$5,339 | -$9,926 | -$19,322 |
| % Margin | – | – | – | – |
| EPS | -4.99 | -4.44 | -8.27 | -16.68 |
| % Growth | -12.4% | 46.3% | 50.4% | – |
| EPS Diluted | -4.99 | -4.44 | -8.27 | -16.68 |
| Weighted Avg Shares Out | 16,789 | 14,416 | 14,410 | 13,904 |
| Weighted Avg Shares Out Dil | 16,789 | 14,416 | 14,410 | 13,904 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,863 | $1,957 | $675 | $0 |
| Interest Expense | $1,468 | $0 | $0 | $0 |
| Depreciation & Amortization | $27 | $111 | $114 | $91 |
| EBITDA | -$82,229 | -$5,228 | -$9,812 | -$19,231 |
| % Margin | – | – | – | – |